NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI). Shareholders who purchased shares of TMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=144423&from= ...

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves Treace Medical and certain officers and/or directors accused of engaging in securities fraud or other unlawful business practices [2]. - Investors who purchased Treace Medical securities during the Class Period can request to be appointed as Lead Plaintiff by June 10, 2025 [3]. Group 2: Financial Performance - On May 7, 2024, Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to $201 million to $211 million [3]. - The company cited competition from minimally invasive osteotomy and Lapiplasty "knockoffs" as headwinds affecting Lapiplasty growth [3]. Group 3: Stock Market Reaction - Following the revenue guidance reduction, Treace Medical's stock price fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4].

NEW YORK, April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc." or the "Company") (NASDAQ: TMCI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Treace Medical Concepts, Inc. investors who were adversely affected by alleged securities fraud between May 8, 2023 and May 7, 2024. Follow the link below to get more information and be contacted by a member of our team:https:/ ...

SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Treace Medical Concepts, Inc. (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. ...

NEW YORK, April 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI).Shareholders who purchased shares of TMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=143837&from=4CLASS ...

Group 1 - A class action lawsuit has been filed against Treace Medical Concepts, Inc. for securities purchased between May 8, 2023, and May 7, 2024 [1] - Investors who purchased Treace Medical securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - The lawsuit alleges that Treace Medical made false or misleading statements regarding competition affecting the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a decline in revenue [5] Group 2 - The Rosen Law Firm, which is representing the investors, has a strong track record in securities class actions, having secured over $438 million for investors in 2019 alone [4] - The firm has been recognized for its success in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 [4] - Investors can join the class action by submitting a form or contacting the firm directly for more information [3][6]

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. alleging securities fraud affecting investors between May 8, 2023, and May 7, 2024 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Treace Medical's primary product, the 3D bunion correction system known as "Lapiplasty," faced decreased demand due to competition [2]. - As a result of the competition, Treace Medical's revenue declined, prompting the company to expedite plans for an alternative product to osteotomy [2]. - The defendants are accused of making materially misleading positive statements regarding the company's business and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, April 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc." or the "Company") (NASDAQ: TMCI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Treace Medical Concepts, Inc. investors who were adversely affected by alleged securities fraud between May 8, 2023 and May 7, 2024. Follow the link below to get more information and be contacted by a member of our team:https:/ ...

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc. for allegedly misleading investors about the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a significant decline in stock price [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Treace Medical failed to disclose competition affecting the demand for its primary product, resulting in a revenue decline [2]. - Following the revelation of these issues, Treace Medical's stock price dropped nearly 63%, closing at $4.17 per share on May 8, 2024 [2]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action, with a deadline to file as lead plaintiff by June 10, 2025 [3]. - Shareholders can choose to remain absent class members without participating in the case [3]. Group 3: Company Background - Treace Medical Concepts, Inc. focuses on advancing surgical management standards for bunion and related midfoot deformities [1].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] Financial Performance - On May 7, 2024, Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to a range of $201 million to $211 million [3] - The company's stock price fell by $6.95, nearly 63%, closing at $4.17 per share on May 8, 2024, following the revenue guidance revision [4] Competitive Landscape - The company reported that competition from minimally invasive osteotomy and Lapiplasty "knockoffs" has created headwinds for the growth of its Lapiplasty product [3]